As a dsRNA‐editing enzyme, ADAR1 shows decreased expression in the brain of AD patients, and this is accompanied by increased levels of transposon‐derived dsRNA [17], which are thought to stimulate the type I interferon signaling pathway through receptors such as RIG‐I or MDA5, further aggravating neuroinflammation [129]. The gene discussed is ADAR; the disease is Alzheimer disease.